A biopharmaceutical company based in Israel is moving closer to revolutionizing the treatment of spinal cord injuries for U.S. patients through regenerative medicine.
NurExone Biologic Inc., Ltd., which completed a reverse takeover (RTO) in June 2022 (TSXV: NRX) (FSE: J90), is developing a biotech platform called ExoTherapy. The company will leverage the platform to develop innovative treatment for damage of the central nervous system.